Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407460 | 0.90 | HTR2C (0.58) | HTR2CDRD3HTR1AIDO1KCNH2 | |
| SCHEMBL6404451 | 0.89 | HTR2C (0.53) | HTR2CDRD3HTR1ALMNASMN1; SMN2 | |
| SCHEMBL6406000 | 0.89 | CXCR3 (0.51) | HTR2CDRD3HTR1ALMNAMTNR1B | |
| SCHEMBL6405348 | 0.87 | KMT2A (0.58) | LMNAMTNR1B | |
| SCHEMBL6407417 | 0.86 | HRH4 (0.52) | HTR2CDRD3HTR1A | |
| SCHEMBL6407639 | 0.86 | HTR2C (0.49) | HTR2CDRD3HTR1ALMNAMTNR1B | |
| SCHEMBL6409545 | 0.85 | GAA (0.55) | HTR2CDRD3HTR1ALMNASMN1; SMN2 | |
| SCHEMBL6409555 | 0.84 | HTR2C (0.58) | HTR2CDRD3HTR1ALMNASMN1; SMN2 | |
| SCHEMBL6409860 | 0.82 | HTR2C (0.48) | HTR2CDRD3HTR1ALMNA | |
| SCHEMBL6405838 | 0.82 | MTNR1B (0.58) | MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | HTR2C 8/4885DRD3 33/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.